This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 30 Mar 2019  |  North America

    Breakthroughs in Non-Alcoholic Steatohepatitis Management

    Multiple Investigational New Drugs with high potential for better treatment outcomes progressing through critical stages of clinical development

    Non-Alcoholic Steatohepatitis or NASH is a liver disorder that is characterized by the build-up of fat in liver in addition to inflammation and liver cell damage eventually progressing to cirrhosis. Currently lifestyle interventions are suggested for the treatment of NASH with no drugs having been approved for the condition. Multiple drugs are at ...

    $4,950.00
  2. 28 Sep 2018  |  North America

    Gene Editing and Gene Therapy Breakthroughs to Propel Mainstream Disease Treatments

    A new wave of gene therapies is set to revolutionize treatments over the next decade for inherited diseases which are either untreatable or which do not have a satisfactory treatment outcome at present

    The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

    $4,950.00
  3. 29 Dec 2017  |  North America

    Innovations in Transdermal Drug Delivery

    Microneedle Technologies Creating Novel Opportunities in Transdermal Drug Delivery Industry

    With the healthcare industry moving toward patient convenience and comfort, pharmaceutical and medical device companies are continuously researching for the most effective, side effect free, convenient route of drug delivery. Transdermal drug delivery is a painless method of delivering drug formulation. Transdermal route of drug administration has ...

    $4,950.00